We show that the novel non-nucleoside RTI, SPV122 synergizes with BRAF and MEK inhibitors to: 1) impair BRAF-mutant melanoma cell growth; 2) induce apoptosis; 3) block cell cycle progression and 4) delay the emergence of resistance in vitro. Here, MAP2K7 is linked to melanoma.